On October 12, 2023, it was announced that the Mount Sinai Health System has received a $12,180,625 grant from the NIH’s National Heart, Lung, and Blood Institute (NHLBI) to compare new treatment options for sickle cell disease and determine which work best for specific patients. “Sickle cell traditionally has been a neglected disease, but it has benefited from a flurry of innovation over the last decade and there are now three new medications approved for the disease,” says Jeffrey Glassberg, MD, Director of the Mount Sinai Sickle Cell Program. “While this is welcome news, clinicians now have a new challenge. No studies have compared the drugs to each other or looked at their use in combination, so there’s very little information to help decide which of the new drugs are best for which patients."
Login Or Register To Read Full Story